We have shown that small molecule IKKε/TBK1 inhibitors reduce viability of DLBCL cell lines, in particular those expressing RELA and STAT3 and that the effects of a panel of inhibitors correlated with potency of the inhibitors against the purified enzymes, which is consistent with on‐target effects. Here, STAT3 is linked to diffuse large B-cell lymphoma.